Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Personalizing extent of breast cancer surgery according to molecular subtypes

(2013) Monica Morrow   BREAST

Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer

(2013) A N Seo et al.   BRITISH JOURNAL OF CANCER

Tumor-Associated Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Breast Cancer Patients

(2013) Hee Jin Lee et al.   Journal of Breast Cancer

Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

(2013) Sherene Loi et al.   JOURNAL OF CLINICAL ONCOLOGY

Multifocal breast cancer documented in large-format histology sections

(2012) Gyula Pekar et al.   CANCER

Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance

(2012) Hyesil Seol et al.   MODERN PATHOLOGY

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer

(2011) Sahar M.A. Mahmoud et al.   JOURNAL OF CLINICAL ONCOLOGY

HER2 molecular subtype is a dominant subtype of mammary Paget’s cells. An immunohistochemical study

(2010) Piotr Sek et al.   HISTOPATHOLOGY

Breast Cancer Molecular Class ERBB2: Preponderance of Tumors With Apocrine Differentiation and Expression of Basal Phenotype Markers CK5, CK5/6, and EGFR

(2010) Rohit Bhargava et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

(2010) M. Elizabeth H. Hammond et al.   Journal of Oncology Practice

Genotypic Intratumoral Heterogeneity in Breast Carcinoma With HER2/neuAmplification

(2009) Matteo Brunelli et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Presenting Features of Breast Cancer Differ by Molecular Subtype

(2009) Lisa Wiechmann et al.   ANNALS OF SURGICAL ONCOLOGY

Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status

(2009) Yeon Hee Park et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Disease-Free Survival According to Degree ofHER2Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial

(2009) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

(2009) Carsten Denkert et al.   JOURNAL OF CLINICAL ONCOLOGY

The Equivocally AmplifiedHER2FISH Result on Breast Core Biopsy

(2008) Joan M. Striebel et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Development of automated brightfield double In Situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence In Situ hybridization (FISH)

(2008) Hiroaki Nitta et al.   Diagnostic Pathology

HER2Status and Benefit from Adjuvant Trastuzumab in Breast Cancer

(2008) Soonmyung Paik et al.   NEW ENGLAND JOURNAL OF MEDICINE